Cargando…

Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients

OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to Octo...

Descripción completa

Detalles Bibliográficos
Autores principales: Klein, Hadar, Asseo, Kim, Karni, Noam, Benjamini, Yuval, Nir-Paz, Ran, Muszkat, Mordechai, Israel, Sarah, Niv, Masha Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884919/
https://www.ncbi.nlm.nih.gov/pubmed/33607252
http://dx.doi.org/10.1016/j.cmi.2021.02.008
_version_ 1783651514612449280
author Klein, Hadar
Asseo, Kim
Karni, Noam
Benjamini, Yuval
Nir-Paz, Ran
Muszkat, Mordechai
Israel, Sarah
Niv, Masha Y.
author_facet Klein, Hadar
Asseo, Kim
Karni, Noam
Benjamini, Yuval
Nir-Paz, Ran
Muszkat, Mordechai
Israel, Sarah
Niv, Masha Y.
author_sort Klein, Hadar
collection PubMed
description OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to October 2020). Patients were recruited via social media and word to mouth and were interviewed up to 4 times, depending on reports of their unresolved symptoms. Inclusion criteria required participants to be residents of Israel aged 18 years or older, with positive COVID-19 real-time PCR results and nonsevere symptoms. The onset, duration, severity and resolution of symptoms were analysed. RESULTS: A total of 44% (45/103), 41% (42/103), 39% (40/103) and 38% (39/103) of patients experienced headache, fever, muscle ache and dry cough as the first symptom respectively. Smell and taste changes were experienced at 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± standard deviation (SD)) after disease onset respectively. Among prevalent symptoms, fever had the shortest duration (5.8 ± 8.6 days), and taste and smell changes were the longest-lasting symptoms (17.2 ± 17.6 and 18.9 ± 19.7 days; durations censored at 60 days). Longer recovery of the sense of smell correlated with the extent of smell change. At the 6-month follow-up, 46% (47/103) of the patients had at least one unresolved symptom, most commonly fatigue (22%, 23/103), smell and taste changes (15%, 15/103 and 8%, 8/103 respectively) and breathing difficulties (8%, 8/103). CONCLUSIONS: Long-lasting effects of mild COVID-19 manifested in almost half of the participants reporting at least one unresolved symptom after 6 months.
format Online
Article
Text
id pubmed-7884919
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-78849192021-02-16 Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients Klein, Hadar Asseo, Kim Karni, Noam Benjamini, Yuval Nir-Paz, Ran Muszkat, Mordechai Israel, Sarah Niv, Masha Y. Clin Microbiol Infect Original Article OBJECTIVES: To characterize longitudinal symptoms of mild coronavirus disease 2019 (COVID-19) patients for a period of 6 months, to potentially aid in disease management. METHODS: Phone interviews were conducted with 103 patients with mild COVID-19 in Israel over a 6-month period (April 2020 to October 2020). Patients were recruited via social media and word to mouth and were interviewed up to 4 times, depending on reports of their unresolved symptoms. Inclusion criteria required participants to be residents of Israel aged 18 years or older, with positive COVID-19 real-time PCR results and nonsevere symptoms. The onset, duration, severity and resolution of symptoms were analysed. RESULTS: A total of 44% (45/103), 41% (42/103), 39% (40/103) and 38% (39/103) of patients experienced headache, fever, muscle ache and dry cough as the first symptom respectively. Smell and taste changes were experienced at 3.9 ± 5.4 and 4.6 ± 5.7 days (mean ± standard deviation (SD)) after disease onset respectively. Among prevalent symptoms, fever had the shortest duration (5.8 ± 8.6 days), and taste and smell changes were the longest-lasting symptoms (17.2 ± 17.6 and 18.9 ± 19.7 days; durations censored at 60 days). Longer recovery of the sense of smell correlated with the extent of smell change. At the 6-month follow-up, 46% (47/103) of the patients had at least one unresolved symptom, most commonly fatigue (22%, 23/103), smell and taste changes (15%, 15/103 and 8%, 8/103 respectively) and breathing difficulties (8%, 8/103). CONCLUSIONS: Long-lasting effects of mild COVID-19 manifested in almost half of the participants reporting at least one unresolved symptom after 6 months. The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2021-05 2021-02-16 /pmc/articles/PMC7884919/ /pubmed/33607252 http://dx.doi.org/10.1016/j.cmi.2021.02.008 Text en © 2021 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Klein, Hadar
Asseo, Kim
Karni, Noam
Benjamini, Yuval
Nir-Paz, Ran
Muszkat, Mordechai
Israel, Sarah
Niv, Masha Y.
Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title_full Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title_fullStr Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title_full_unstemmed Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title_short Onset, duration and unresolved symptoms, including smell and taste changes, in mild COVID-19 infection: a cohort study in Israeli patients
title_sort onset, duration and unresolved symptoms, including smell and taste changes, in mild covid-19 infection: a cohort study in israeli patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884919/
https://www.ncbi.nlm.nih.gov/pubmed/33607252
http://dx.doi.org/10.1016/j.cmi.2021.02.008
work_keys_str_mv AT kleinhadar onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT asseokim onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT karninoam onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT benjaminiyuval onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT nirpazran onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT muszkatmordechai onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT israelsarah onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients
AT nivmashay onsetdurationandunresolvedsymptomsincludingsmellandtastechangesinmildcovid19infectionacohortstudyinisraelipatients